welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
expertly curated content related to this topic
-
Janice L. Berliner, MSJanice has been a clinical genetic couns...
-
Marina Biotech Announces $1.1 MM Convertible Preferred Stock FinancingMarina Biotech, Inc. ( OTCQB : MRNA ), a...
-
RARE on the RoadThe EveryLife Foundation and Global Gene...
-
UMass Memorial Medical CenterUMass Memorial Medical Center's speciali...
-
Cancer Support CommunityAnyone impacted by a diagnosis of cancer...
-
Scott K. Kuwada, MDScott K. Kuwada, MD joined The Queen’s...